Absci (ABSI) Depreciation & Amortization (CF) (2020 - 2026)
Absci (ABSI) posted Depreciation & Amortization (CF) of $2.7 million for Q1 2026, down 3.54% sequentially from $2.8 million in Q4 2025, and down 11.2% YoY from $3.1 million in Q1 2025.
Analysis
Absci (ABSI) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Absci has reported Depreciation & Amortization (CF) for 7 years, with the latest figure at $2.7 million in Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 11.2% year-over-year to $2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.4 million (down 12.63% YoY) and the FY2025 annual result came in at $11.7 million, down 12.3% from the prior year.
- Depreciation & Amortization (CF) retreated to $2.7 million in Q1 2026 per ABSI's latest filing, from $2.8 million in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $3.6 million in Q4 2022 and troughed at $2.7 million in Q1 2026.
- A 5-year average of $3.2 million and a median of $3.4 million in 2024 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2022 and 2025: Depreciation & Amortization (CF) soared 510.5% in 2022, then dropped 15.29% in 2025.
- Over 5 years, Depreciation & Amortization (CF) stood at $3.6 million in 2022, then slipped by 2.84% to $3.5 million in 2023, then dropped by 7.18% to $3.2 million in 2024, then decreased by 12.55% to $2.8 million in 2025, then fell by 3.54% to $2.7 million in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $2.7 million, $2.8 million, and $2.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Absci | 1.39 Bn | 1.19 Bn | - | 2.70 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.70 Mn |
| Mar 31, 2026 | 2.73 Mn |
| Dec 31, 2025 | 2.83 Mn |
| Sep 30, 2025 | 2.84 Mn |
| Jun 30, 2025 | 3.00 Mn |
| Mar 31, 2025 | 3.07 Mn |
| Dec 31, 2024 | 3.23 Mn |
| Sep 30, 2024 | 3.36 Mn |
| Jun 30, 2024 | 3.38 Mn |
| Mar 31, 2024 | 3.42 Mn |
| Dec 31, 2023 | 3.48 Mn |
| Sep 30, 2023 | 3.51 Mn |
| Jun 30, 2023 | 3.50 Mn |
| Mar 31, 2023 | 3.50 Mn |
| Dec 31, 2022 | 3.59 Mn |
| Sep 30, 2022 | 3.40 Mn |
| Jun 30, 2022 | 3.14 Mn |
| Mar 31, 2022 | 2.91 Mn |
| Dec 31, 2021 | 2.76 Mn |
| Sep 30, 2021 | 2.22 Mn |